Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmirtazapine extension in chronic primary insomnia
NCT00750919Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of esmirtazapine in Chronic Primary Insomnia, sponsored by Merck & Co. Primary endpoints: Total Sleep Time at Week 26, Adverse Events up to 30 weeks and 1 more. Started Oct 2008; status: terminated.
02
Drugs
esmirtazapine
03
Conditions
Chronic Primary Insomnia
Beyond the preview
Go deeper on NCT00750919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750919.